Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada

BACKGROUND: The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary syndromes. Recently, Effient (prasugrel [Eli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lordkipanidzé, Marie, Marquis-Gravel, Guillaume, Tanguay, Jean-François, Mehta, Shamir R., So, Derek Y.F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209390/
https://www.ncbi.nlm.nih.gov/pubmed/34169260
http://dx.doi.org/10.1016/j.cjco.2020.11.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209390/
https://www.ncbi.nlm.nih.gov/pubmed/34169260
http://dx.doi.org/10.1016/j.cjco.2020.11.021

Ejemplares similares